

For Immunization Managers



For Immunization Managers

RSV Vaxview

WEEKLY RSV VACCINATION DASHBOARD

Weekly Respiratory Syncytial Virus (RSV) Vaccination Dashboard

The Weekly RSV Vaccination Dashboard is designed to share weekly RSV vaccination data, including coverage estimates and intent for vaccination, using a variety of data sources including surveys, healthcare claims, electronic medical records, and immunization information systems (IIS) data. The Dashboard will be updated weekly as new data become available. Please [email](#) to share any feedback.

Data Summary

Adults 60+ Coverage (NIS)

[Data and Charts for Adults 60+ Coverage >](#)

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among [adults 60 years and older](#) are based on data from CDC's National Immunization Survey-Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report.

- As of January 27, 2024, an estimated 20.8% (95% Confidence Interval: 19.8%-21.7%) of adults 60 years and older reported having received an RSV vaccine.

- An additional 11.8% (10.1%-13.5%) reported that they definitely plan to get vaccinated.
 - White adults had higher vaccination coverage than adults in all other race and ethnicity groups, with coverage ranging from 4.9% (1.6%-8.2%) among Pacific Islander and Native Hawaiian adults to 23.3% (22.1%-24.4%) among non-Hispanic White adults.
 - Vaccination coverage has also consistently varied by age, poverty status, health insurance status, urbanicity, disability status, gender identity, and chronic medical condition.
 - Across states and District of Columbia, receipt of an RSV vaccine was lowest in Mississippi [11.5% (8.8%-14.2%)] and highest in Massachusetts [30.7% (24.4%-36.9%)].
 - Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are [available](#).
-

Pregnant Persons Coverage (VSD)

[Data and Charts for Pregnant Persons Coverage >](#)

Pregnant Persons RSV Vaccination Coverage

RSV vaccination coverage estimates for [pregnant persons](#) 18 to 49 years are based on data from CDC's [Vaccine Safety Datalink](#). Estimates of vaccination coverage are based on electronic health data from multiple integrated health systems.

- As of January 27, 2024, among persons who were pregnant and ≥ 32 weeks gestation since September 22, 2023, overall coverage with the RSV vaccine was 16.2%.
 - Vaccination coverage was highest among non-Hispanic Asian (22.8%) pregnant persons and lowest among non-Hispanic Black (9.5%) pregnant persons.
-

Adult Vaccinations Administered (IQVIA)

[Data and Charts for Adult Vaccinations Administered >](#)

RSV Vaccinations Administered in Pharmacies and Medical Offices (Data Source: IQVIA)

RSV vaccinations administered at pharmacies and physician medical offices for [adults 60 years and older](#) based on healthcare claims data.

- As of January 13, 2024, an estimated 8.83 million doses were administered in pharmacies and an estimated 260,239 doses were administered in physician medical offices to adults 60 years and older.
-

Nirsevimab Coverage and Intent for Infants (NIS)

[Data and Charts for Nirsevimab Coverage and Intent for Infants >](#)

Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females aged 18-49 years with infants under the age of < 8 months, females aged 18-49 years who are currently pregnant, and females aged 18-49 years who are currently trying to get pregnant, are based on data from CDC's National Immunization Survey-Adult COVID Module. Estimates of

nirsevimab coverage and intent are based on respondent self-report.

- As of December 2023, among females with an infant <8 months, 28.7% reported that their infant received nirsevimab.
- An additional 31.4% reported that they definitely plan to get nirsevimab for their infant.
- Among females who are currently pregnant, 33.9% reported that they definitely plan to get nirsevimab for their infant, and among females who are trying to get pregnant, 44.2% reported that they definitely plan to get nirsevimab for their infant.

Data & Charts



Adults 60+ Coverage and Intent

(Data Source: NIS)



Pregnant Persons Coverage

(Data Source: VSD)



Adult Vaccinations Administered

(Data Source: IQVIA)



Nirsevimab Coverage and Intent for Infants

(Data Source: NIS)

Related Pages

Prevent RSV

[Adults 60 years and older](#) and [pregnant persons](#) can protect themselves from RSV.

Learn more about [RSV](#).